Our findings support the efficacy of combined targeting of RET and EGFR in CCDC6-RET NSCLC and thyroid cancer cells, successfully preventing tumor cell growth under RET-resistant conditions. This evidence concerns the gene EGFR and non-small cell lung carcinoma.